Effect of soy protein varying in isoflavone content on serum lipids in healthy young men

McVeigh, Brianne L.; Dillingham, Barbara L.; Lampe, Johanna W.; Duncan, Alison

doi:10.1093/ajcn/83.2.244

Cited by 73 publications

(62 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,7,8,[22][23][24] In our study the isoflavones were not determined in the b-conglycinin fraction; however, McVeigh et al 25 and Adams et al 26 showed in humans and monkeys that a soy protein diet low in isoflavones produces the same effect on cholesterol levels as a soy protein diet high in isoflavones. These products may be vastly different when comparing studies and=or distinct sources.…”

Section: B-conglycinin In Hypercholesterolemic Ratscontrasting

confidence: 55%

Soy β-Conglycinin (7S Globulin) Reduces Plasma and Liver Cholesterol in Rats Fed Hypercholesterolemic Diet

Ferreira

Silva

Demonte

et al. 2011

Journal of Medicinal Food

View full text Add to dashboard Cite

The aim of this study was to examine the comparative hypocholesterolemic effect of soybean 7S fraction in rats fed a high-cholesterol diet. Soybean 7S globulin (b-conglycinin) was administered orally once a day to rats, and the effects were measured after 28 days. Wistar rats were divided into four groups: standard diet (STD) (casein alone), hypercholesterolemic (HC) diet (STD plus 1 g=100 g cholesterol and 0.5 g=100 g cholic acid), HCþ7S 1 diet (HC diet plus 200 mg of 7S=kg of body weight=day), and HCþ7S 2 diet (HC diet plus 300 mg of 7S=kg of body weight=day). Food intake, weight gain, animals' growth, and feeding efficiency ratio were similar among the STD and three HC groups, indicating that these parameters were not affected by treatments. Animals that had received different doses of soybean 7S globulin had lower total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL)=high-density lipoprotein (HDL) ratio in serum and lower levels of hepatic TC and TG than those fed only the HC diet. The atherogenic indexes of HCþ7S 1 and HCþ7S 2 groups were 40% and 55% lower than that of the HC group, respectively. The results showed that the oral daily administration of bconglycinin in the diet to HC rats, at between 1.85% and 2.75% of total ingested protein, promotes the reduction of TC, LDLcholesterol, and TG and an increase in HDL-cholesterol in the plasma, besides a small but significant reduction in cholesterol and TG levels in the liver of the animals as well as a reduced atherogenic index.

show abstract

Section: B-conglycinin In Hypercholesterolemic Ratscontrasting

confidence: 55%

Soy β-Conglycinin (7S Globulin) Reduces Plasma and Liver Cholesterol in Rats Fed Hypercholesterolemic Diet

Ferreira

Silva

Demonte

et al. 2011

Journal of Medicinal Food

View full text Add to dashboard Cite

show abstract

“…Although the clinical characteristics of subjects in the present study may have contributed to the lack of change observed in plasma lipids, other dietary substances (such as soy protein) have been shown to improve plasma lipids in young normocholesterolemic subjects (Wong et al, 1998;Merz-Demlow et al, 2000;McVeigh et al, 2006). In addition, prospective studies have reported a relationship between lipid concentrations within the normal range and future CHD (Klag et al, 1993;Strandberg et al, 2004), and current public health recommendations suggest lower goals for optimal plasma lipid concentrations (Expert Panel, 2001;Grundy et al, 2004).…”

Section: Discussionmentioning

confidence: 75%

Probiotic capsules do not lower plasma lipids in young women and men

et al. 2007

View full text Add to dashboard Cite

Objective: To investigate the effect of probiotic capsules on plasma lipids. Design: A randomized, single-blinded, placebo-controlled, parallel-arm trial. Subjects: Fifty-five normocholesterolemic subjects ages 18-36 (33 premenopausal women and 22 men). Intervention: Each subject consumed either three probiotic capsules each containing a total of 10 9 colony-forming units Lactobacillus acidophilus and Bifidobacterium longum and 10-15 mg fructo-oligosaccharide or three placebo capsules daily for 2 months (men) or two menstrual cycles (women). Plasma lipids were measured before and following the intervention (during the early follicular phase for women). Results: Plasma concentrations of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride were not altered by consumption of probiotic or placebo capsules and were not different between treatment groups following the intervention. Conclusions: These results do not support a beneficial effect of Lactobacillus acidophilus strain DDS-1 and Bifidobacterium longum strain UABL-14 on plasma lipids in normocholesterolemic young women and men. Sponsorship: Supported by the Minnesota Agricultural Experiment Station and UAS Laboratories.

show abstract

“…Fourteen of the remaining 19 RCTs had a parallel design while five (Evans et al, 2007;Greany et al, 2004;McVeigh et al, 2006;Steinberg et al, 2003;Thorp et al, 2008) had a cross-over design. All subjects (n=1,947) who entered data analysis had normal or moderately elevated blood LDLcholesterol concentrations at baseline.…”

Section: Scientific Substantiation Of the Claimed Effectmentioning

confidence: 99%

“…In eight of the 19 RCTs, background diet was not assessed and possible confounding effects resulting from differences in background diet between the intervention and the control were not taken into account. Dietary intake was assessed in the remaining 11 studies, either by food frequency questionnaires (Allen et al, 2007;Crouse et al, 1999;Kreijkamp-Kaspers et al, 2004;Thorp et al, 2008) or by three-day dietary records (Baum et al, 1998;Greany et al, 2004;McVeigh et al, 2006;Santo et al, 2008;Steinberg et al, 2003;Teixeira et al, 2000;Van Horn et al, 2001). …”

Section: Scientific Substantiation Of the Claimed Effectmentioning

confidence: 99%

“…Fourteen of the 19 RCTs reported no significant effect of ISP on blood LDL (Allen et al, 2007;Evans et al, 2007;Greany et al, 2004;Hoie et al, 2007;Kreijkamp-Kaspers et al, 2004;Maesta et al, 2007;McVeigh et al, 2006;Santo et al, 2008;Steinberg et al, 2003;Teede et al, 2001;Teede et al, 2005;Thorp et al, 2008;Van Horn et al, 2001) or on non-HDL (Sagara et al, 2003) cholesterol concentrations relative to controls. These studies together considered 1,520 subjects for data analysis (9-98 subjects per group/period) and provided 20 to 40 g per day of ISP for four weeks to 12 months.…”

Section: Scientific Substantiation Of the Claimed Effectmentioning

confidence: 99%

See 1 more Smart Citation

Scientific Opinion on the substantiation of a health claim related to isolated soy protein and reduction of blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation (EC) No 1924/2006

Products¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following an application from the European Natural Soyfood Manufacturers Association (ENSA), the European Vegetable Protein Federation (EUVEPRO) and the Soya Protein Association (SPA), submitted pursuant to Article 14 of Regulation (EC) No 1924 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to isolated soy protein (ISP) and reduction of blood LDL-cholesterol concentrations, referring to disease risk reduction. The food constituent that is the subject of the health claim, ISP (as defined by the applicant), is sufficiently characterised in relation to the claimed effect. A reduction of blood LDL-cholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD. In weighing the evidence, the Panel took into account that under similar conditions four randomised controlled trials (RCTs) reported an effect of ISP on blood LDL/non-HDL cholesterol concentrations, whereas 14 RCTs did not report such an effect, and another RCT showed no consistent effects. The Panel also took into account that most of these RCTs were at high risk of bias, that differences in the results obtained between trials appear unrelated to the dose of ISP used, to sample size or to study duration, and that the evidence provided in support of a possible mechanism was not convincing. A cause and effect relationship has not been established between the consumption of ISP (as defined by the applicant) and a reduction in blood LDL-cholesterol concentrations. The scope of the application was proposed to fall under a health claim referring to disease risk reduction. © European FoodThe food constituent that is the subject of the health claim is "protein-rich soybean component with limited quantities of macro-and micronutrients", which upon a request from EFSA was further defined by the applicant as ISP. The Panel considers that ISP (as defined by the applicant) is sufficiently characterised in relation to the claimed effect.The claimed effect is "reduction of total and LDL-cholesterol in healthy subjects with normal or mildly elevated blood cholesterol; a reduction of total and LDL cholesterol has been shown to reduce the risk of heart disease". The target population proposed by the applicant is healthy subjects with normal or mildly elevated blood cholesterol levels. The Panel considers that reduction of blood LDLcholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.The applicant identified 23 RCTs, which used ISP and one RCT which used the water insoluble fraction of a partially hydrolysed soy protein as interventions for the scientific substantiation of the claim, and presented an unpublished meta-analysis of 23 of these 24 RCTs. In addition, six RCTs, which used whole soy foods, and eight observational studies were provided as well as one animal a...

show abstract

Effect of soy protein varying in isoflavone content on serum lipids in healthy young men

Abstract: Soy protein, regardless of isoflavone content, modulates serum lipid ratios in a direction beneficial for cardiovascular disease risk in healthy young men.

Cited by 73 publications

References 48 publications

Soy β-Conglycinin (7S Globulin) Reduces Plasma and Liver Cholesterol in Rats Fed Hypercholesterolemic Diet

Soy β-Conglycinin (7S Globulin) Reduces Plasma and Liver Cholesterol in Rats Fed Hypercholesterolemic Diet

Probiotic capsules do not lower plasma lipids in young women and men

Scientific Opinion on the substantiation of a health claim related to isolated soy protein and reduction of blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation (EC) No 1924/2006

Contact Info

Product

Resources

About